NewEdge Advisors’s 10x Genomics TXG Stock Holding History

NewEdge Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.3K	Hold	426	–	–	﹤0.01%	3416
2026 Q1	$9.04K	Buy	+426	New	+$8.52K	﹤0.01%	3426
2024 Q2	–	Sell	-106	Closed	-$3.98K	–	4003
2024 Q1	$3.98K	Sell	106 -425	-80%	-$18.7K	﹤0.01%	3211
2023 Q4	$29.7K	Buy	531 +406	+325%	+$17.7K	﹤0.01%	2416
2023 Q3	$5.16K	Hold	125	–	–	﹤0.01%	2800
2023 Q2	$6.98K	Sell	125 -123	-50%	-$6.66K	﹤0.01%	2713
2023 Q1	$13.8K	Sell	248 -531	-68%	-$24.8K	﹤0.01%	2470
2022 Q4	$23.5K	Buy	+779	New	+$25.5K	﹤0.01%	2067
2021 Q1	–	Sell	-7,373	Closed	-$1.04M	–	1115
2020 Q4	$1.04M	Buy	+7,373	New	+$1.07M	0.03%	407

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NewEdge Advisors's TXG Position: Q2 2026 in Review

NewEdge Advisors held its 10x Genomics (TXG) position steady in Q2 2026 at 426 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3416.

NewEdge Advisors first reported a position in TXG in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.04M in Q4 2020. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

NewEdge Advisors held 426 shares of 10x Genomics worth $16.3K as of Q2 2026.
NewEdge Advisors left its 10x Genomics share count unchanged in Q2 2026.
10x Genomics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3416 holding.
NewEdge Advisors first reported a position in 10x Genomics in Q4 2020 and has held it in 9 quarters since.
NewEdge Advisors's 10x Genomics position peaked at $1.04M in Q4 2020.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.